FDA approves Brilinta for heart disease

Thursday 21 July 2011

The US Food and Drug Administration has approved Brilinta (ticagrelor), an oral antiplatelet medicine, to reduce the rate of cardiovascular death and heart attack in adult patients with acute coronary syndrome. The developer is AstraZeneca Plc.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States